For the quarter ending 2025-09-30, INO had $12,216,043 increase in cash & cash equivalents over the period. -$21,641,446 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -88,710,781 | - |
| Depreciation | 350,198 | 727,518 |
| Amortization of operating lease right-of-use assets | 399,458 | 757,602 |
| Change in fair value of common stock warrant liabilities | 20,680,868 | - |
| Non-cash stock-based compensation | 757,086 | 2,234,141 |
| Non-cash interest on senior convertible notes | 0 | 0 |
| Amortization of discounts on investments | -63,870 | 13,003 |
| Loss on sales of short-term investments | -182,904 | -707,984 |
| Loss on disposal of fixed assets | 0 | 0 |
| (gain) loss on equity investment in affiliated entity | 881,886 | - |
| Net unrealized gain on available-for-sale equity securities | 1,104,782 | - |
| Accounts receivable from affiliated entity | 138,278 | -358,744 |
| Prepaid expenses and other current assets | -908,843 | 1,789,912 |
| Other assets | 0 | 32,822 |
| Accounts payable and accrued expenses, including due to affiliated entity | -350,130 | -1,497,805 |
| Accrued clinical trial expenses | -555,014 | -510,876 |
| Operating lease right-of-use assets and liabilities, net | -638,001 | -1,206,959 |
| Grant funding liability, including from affiliated entity | 42,152 | 0 |
| Net cash used in operating activities | -21,573,495 | -47,685,386 |
| Purchases of investments | 0 | 4,946,073 |
| Proceeds from sale or maturity of investments | 8,935,184 | 10,266,689 |
| Purchases of capital assets | 67,951 | 90,303 |
| Net cash provided by investing activities | 8,867,233 | 5,230,313 |
| Repayment of convertible senior notes | 0 | 0 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | - | 0 |
| Proceeds from issuance of warrants, net of issuance costs-Pre Funded Warrants | 0 | - |
| Proceeds from issuance of common stock, net of issuance costs | 7,185,128 | 1,102,149 |
| Proceeds from issuance of warrants, net of issuance costs-Warrant | 16,986,830 | - |
| Proceeds from exercise of warrants and pre-funded warrants | 752,134 | - |
| Proceeds from stock option exercises | 0 | 0 |
| Taxes paid related to net share settlement of equity awards | -1,787 | -108,996 |
| Net cash provided by financing activities | 24,922,305 | 993,153 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0 |
| (decrease) increase in cash and cash equivalents | 12,216,043 | -41,461,920 |
| Cash and cash equivalents at beginning of period | 65,813,297 | - |
| Cash and cash equivalents at end of period | 36,567,420 | - |
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)